ABSTRACT

Background: Depressive disorder is a prevalent psychiatric disorder, which affects 21% of the world population. Many drugs are available as effective antidepressants. But still there is necessity of developing novel compounds with minimized side effects. Hence this study was aimed to investigate the antidepressant activity of novel furan compound in albino mice.

Methods: Antidepressant activity of novel furan compound was investigated by using forced swimming test (FST) and tail suspension test (TST) models. Fluoxetine was used as standard drug in this study.

Results: It has been observed from our study that medium dose of test compound (10 mg/kg) reduced duration of immobility time to 35 seconds when compared to control group (147 seconds) in FST model. In TST model, the test compound of medium dose (10 mg/kg) had produced 83% protection against passive behaviour which is almost similar to standard drug fluoxetine (100%).

Conclusions: The results of the specifies that compared to other two doses of test compound (5 mg/kg and 20 mg/kg), medium dose of test compound found as an effective dose for treating depression produced due to stress. However, further expansion of the study is needed for this compound to prove as a novel effective antidepressant compared to other drugs available for treating depression.

Keywords: Antidepressant activity, FST, Novel furan compound, TST

INTRODUCTION

The World Health Organization (2010) estimates that 151 million people suffer from depression and around 844 thousand people die by suicide every year. Globally, mental health conditions account for 13% of the total burden of disease and 31% of all years lived with disability. More than 80% of the global burden of disease due to mental health conditions can be found in low- and middle-income countries.1
Depression is a state of low mood and aversion to activity that can affect person's thoughts, behavior, feelings and physical well-being. Patients with major depression have symptoms related to changes in brain monoamine transmitters, specifically dopamine, serotonin, and norepinephrine.

In spite of the availability of many anti-depressant drugs, depression continues to be a major medical problem. Newer generations of antidepressants have provided pharmacologic interventions that are effective and better tolerated than older agents. Even though, there is always a need for the development of new drugs for the treatment of depression as the existing classes of antidepressants are associated with several limitations like adverse effects, delay in the onset of antidepressant action, poor response in certain individuals, etc.

The development of newer and safer therapeutic agents would benefit the treatment modalities of depression. In this study, a novel substituted furan derivative is synthesized and aimed to find its antidepressant activity at 5-20 mg/kg in mice by using forced swimming test (FST) and tail suspension test (TST).

METHODS

Animals

Swiss albino male mice weighing 20-25 g were selected for the study and maintained for 7 days in the animal house under standard laboratory conditions. The animals were fed with standard rat pellet and water ad libitum. The animals were allowed to acclimatize to the laboratory conditions. All procedures were performed during the light phase of the cycle. All the experiments were conducted after obtaining permission from the Institutional Animal Ethics committee.

Antidepressant activity

The synthesized test compound was screened for antidepressant activity by tail suspension method and forced swimming test in albino mice. A total of 60 mice were selected for the study, 30 mice in each method. Animals were divided into five groups consisting of 6 animals in each. Test drug should be suspended in 10% Tween80 solution just before administration to the animals. The grouping of animals was as follows:

- Control group received 10% tween 80 orally
- Standard group received fluoxetine 20 mg/kg orally
- Test group 1 received 5 mg/kg substituted furan compound orally
- Test group 2 received 10 mg/kg substituted furan compound orally
- Test group 3 received 20 mg/kg substituted furan compound orally

**Forced swim test (FST)**

Depression was produced in albino mice by forcing them to swim individually in a glass jar (25×12×25 cm³) containing fresh water of 15 cm height and maintained at 25°C (±3°C). After an initial 2 minute period of vigorous activity, each animal assumed a typical immobile posture. A mouse was considered to be immobile when it remained floating in the water without struggling, making only minimum movements of its limbs necessary to keep its head above water. The total duration of immobility was recorded during the next 4 min of total 6 min test. A decrease in the duration of immobility is indicative of an antidepressant like effect. Duration of immobility is measured in controls and animals treated with various doses of a test drug or standard.

Duration of immobility = \( \frac{\text{Standard} - \text{control}}{\text{Control}} \times 100 \)

**Tail suspension test (TST)**

Mice are housed in plastic cages for at least 10 days prior to testing in a 12 h light cycle with food and water freely available. Animals are transported from the housing room to the testing area in their own cages and allowed to adapt to the new environment for 1 h before testing. Groups of 6 animals are treated with the test compounds or the vehicle orally 60 min prior to testing. For the test the mice are suspended on the edge of a shelf 58 cm above a table top by adhesive tape placed approximately 1 cm from the tip of the tail. The duration of immobility is recorded for a period of 5 min. Mice is considered immobile when they hang passively and completely motionless for at least 1 min. The percentage of animals showing the passive behaviour was counted and compared with vehicle treated controls.

**Statistical analysis**

Values obtained for forced swimming test was given as mean±SD. All the groups were analysed by one-way ANOVA followed Dunnet’s multiple comparison test. P <0.05 was considered statistically significant. The values obtained in tail suspension test were given as percentage of animals protected against passive behaviour.

RESULTS

**Forced swimming test**

Table 1 shows the duration and percentage inhibition of immobility time in mice treated with tween 80, fluoxetine, low dose (5 mg/kg), medium dose (10 mg/kg) and high dose (20 mg/kg) of test compound. The animals that received medium dose showed significant reduction in immobility time (35.83±9.867 seconds) compared to control group (147.33±8.589 seconds).
Table 1: Effect of test compound on duration and percentage inhibition of immobility in mice by FST method.

| Group                        | Mean (sec)±SD | % Inhibition |
|------------------------------|---------------|--------------|
| Control (10% tween 80 orally) | 147.33±8.589 |              |
| Standard (fluoxetine 20 mg/kg orally) | 27.83±3.869a | 81.08        |
| Test group-1 (test drug 5 mg/kg, orally) | 54.00±8.075b | 63.30        |
| Test group-2 (test drug 10 mg/kg, orally) | 35.83±9.867a | 75.65        |
| Test group-3 (test drug 20 mg/kg, orally) | 41.67±9.74a  | 71.69        |

a = P <0.05 and considered as significant when compared with control; b = P <0.001 and considered as significant when compared with control.

Tail suspension test

Figure 1 shows the percentage number of animals showing passive behaviour. None of the animals that received fluoxetine did not show any passive behaviour (0/6). 66.6% of animals (4/6) that received low dose of drug (5 mg/kg) showed passive behaviour. The group of animals that received medium (10 mg/kg) and higher dose (20 mg/kg) exhibited passive behaviour by 16.66% (1/6) and 33.33% (2/6) respectively.

Fluoxetine was used as standard drug in this study in both models because it acts by selectively inhibiting reuptake of serotonin. The antidepressant activity of the test drug evaluated in this study was a novel furan compound. A number of furan compounds were proved of having significant antidepressant activity. In this study the test drug showed a significant antidepressant activity when compared with control group in both the models.

In the FST the percentage decrease in the immobility duration in mice treated with tween 80, fluoxetine, low dose (5 mg/kg), medium dose (10 mg/kg), high dose (20 mg/kg) were evaluated. The fluoxetine had shown maximum efficacy of 81% inhibition. The medium dose (5 mg/kg) had shown 75.05% inhibition efficacy comparable to the standard drug fluoxetine. The low dose and high doses had shown less efficacy compared to medium dose (10 mg/kg) test compound.

In TST model the percentage inhibition of protection against passive behaviour (immobility) was investigated. Fluoxetine produced 100% protection and test drug in high dose (20 mg/kg) had also produced 100% protection against passive behaviour comparably equal to fluoxetine. The medium dose test compound (10 mg/kg) had produced 83% protection against passive behaviour compared to fluoxetine. The low dose test compound (5 mg/kg) had produced 33.3% protection against passive behaviour.

DISCUSSION

The present study was conducted to assess the antidepressant activity of novel furan compound in albino mice by using FST and TST methods. Stress plays an important role in developing depression. FST and TST animal models create physical stress and there by leading to depression. These models of depression provide a rapid and reliable behaviour screening test for antidepressants. The immobility has been expected to reflect a state of behavioural despair and failure to adapt to the stress. Antidepressant drugs decrease immobility time in both FST and TST.

Figure 2 shows the percentage number of animals protected against passive behaviour in mice after treating with tween 80, Fluoxetine, low dose (5 mg/kg), medium dose (10 mg/kg) and high dose (20 mg/kg) test compound. The animals that received medium dose of test compound had shown 83.3% protection (5/6) against passive behaviour that was almost similar to group of animals that received fluoxetine 100% (6/6). Animals treated with high and low dose of test compound exhibited 66.66% (4/6) and 33.33% (2/6) of protection against passive behaviour respectively.
behaviour. All doses have produced significant antidepressant activity and efficacy was proportionate to the dose against activity.

CONCLUSION

Results in FST model showed that the test compound at medium dose (10 mg/kg) showed significant diminution of immobility time (35 seconds) when compared to other groups. Similarly, in TST model also the animals that received medium dose (10 mg/kg) showed significant protection (83.3%) against passive behaviour compared to other groups. These results specifies that compared to other two doses of test compound (5 mg/kg and 20 mg/kg), medium dose of test compound can be effectively used for treating depression produced due to stress. Further study need to be extended for this compound to prove as a novel effective antidepressant compared to other drugs available for treating depression.

Funding: No funding sources
Conflict of interest: None declared

Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Sindhu T, Mamatha A, Sahith Reddy K, Venkateshwarlu K. Antidepressant activity of pyrimidine derivatives in mice. J Drug Med. 2013;5:129-34.
2. Riyaz M, Kumar A, Raj V, Singh S. Review on antidepressant activity in behavioral models. Int J Pharm Integrated Life Sci. 2013;1(3):16-29.
3. Dipiro T. Joseph Pharmacotherapy. A Pathophysiologival Approach. 6th edition. McGraw-Hill medical publishing division; 2014; 1235-1256.
4. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: Depression and anxiety disorders. In: Hardman JG, Limbrid LE, Goodman A, et al, editors. Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2000:447-484.
5. Warner V, Weissman MM, Mufson L, Wickramaratne PJ. Grandparents, parents, and grandchildren at high risk for depression: Three-generation study. J Am Acad Child Adolesc Psychiatry. 1999;38:289-96.
6. Kendler KS, Prescott CA. A population based twin study of lifetime major depression in men and women. Arch Gen Psychiatry. 1999;56:39-44.
7. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69:4-7.
8. Vinayak M, Ruckmani A, Chandrashekar K, Konda VGR, Madhavi E, Swati B. Antidepressant activity of ethanolic extract Piper betle leaves in mice. Curr Res in Neurosci. 2012;2(1):11-6.
9. Singh GK, Garabadu D, Muruganandam AV, Joshi VK, Krishnamurthy S. Antidepressant activity of Asparagus racemosus in rodent models. Pharmacol Biochem Behav. 2009;91:283-90.
10. Shobe A, Chowta M, Fallempati G, Rai A, Singh A. Evaluation of antidepressant activity of vanillin in mice. Indian J Pharmacol. 2013;45(2):141-4.
11. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977;229:327-36.
12. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacol (Berl). 1985;85:367-70.
13. Ahmed Amany AE, Al-Rashed Nawal M, Al-Rasheed Noof M. Antidepressant-like activities of rosiglitazone in the rat forced swim and the mouse tail suspension tests. Saudi Pharma J. 2009;1(17):51-61.
14. Plaznik A, Tamborska E, Hauptmann M, Bidzinski A, Kostowski W. Brain neurotransmitter systems mediating behavioral deficits produced by inescapable shock treatment in rats. Brain Res. 1988;447:122-32.
15. Manavi C, Pinki V, Gautam P. Comparative evaluation of Bacopa monniera and Panax quinquefolium in experimentiel and depressive models in mice. Indian J Exp Biol. 2010;48:306-31.
16. Ramana Murty Kadali SLDV, Das MC, Srinivasa Rao ASR, Karuna Sri G. Antidepressant Activity of Brahmi in Albino Mice. J Clin Diagn Res. 2014;8(3):35-7.

Cite this article as: Jayakumar JK, Nityakarnam, Kumar KP, Supriya. Pharmacological evaluation of substituted 4, 5-diphenyl furan-3-carboxamide compound for antidepressant activity in mice. Int J Basic Clin Pharmacol 2017;6:39-42.